Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells

{
  "id": "MLC-T-ONC-011386",
  "term": "Autologous Anti-CD19/CD20 Bispecific Nanobody-based CAR-T cells",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that is nanobody-based and specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD19/CD20 bispecific nanobody-based CAR-T cells target and bind to CD19- and CD20-expressing tumor B-cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.",
  "synonyms": [
    "autologous CD19/CD20 bispecific CAR T cells",
    "autologous anti-CD19/CD20 bispecific nanobody-derived CAR-T cells",
    "autologous anti-CD19/20 bispecific CAR-T cells",
    "autologous CD19/CD20 bispecific CAR-T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-cd19-cd20-bispecific-nanobody-based-car-t-cells/"
}